IP Library Granted Patent US 7,563,598
Granted Patent B2
US 7,563,598 · App. 11/487,128 · Granted Jul 21, 2009

Detection of truncation mutations by mass spectrometry

Assignee: Ambergen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,563,598
App. No.
11/487,128
Granted
Jul 21, 2009
Kind
B2
Abstract

This invention relates to the detection and analysis by mass spec of nascent proteins, and in particular truncated proteins, translated within cellular or cell-free translation systems. N-terminal and C-terminal epitopes introduced into these nascent proteins permit rapid and efficient isolation, as well as a mass difference.

Claims (22)

1. A method, comprising:

a) providing:

i) a nucleic acid sequence encoding a polypeptide, said polypeptide being between 10 and 150 amino acids in length; and

ii) a reconstituted in vitro translation system comprising recombinant proteins, at least one protease inhibitor and isotopically-depleted amino acids;

b) introducing said nucleic acid into said reconstituted translation system under conditions such that said polypeptide is produced, said polypeptide comprising isotopically-depleted amino acids; and

c) determining the molecular mass of said polypeptide by mass spectrometry.

2. The method of claim 1 , wherein said isotopically-depleted amino acids are 13 C-depleted.

3. The method of claim 1 , wherein said isotopically-depleted amino acids are 15 N-depleted.

4. The method of claim 1 , wherein said isotopically-depleted amino acids are 13 C- and 15 N -depleted.

5. A method, comprising:

a) providing:

i) a first nucleic acid sequence encoding a polypeptide comprising a wild-type sequence;

ii) a second nucleic acid sequence encoding a truncated polypeptide of said wild-type sequence, said truncated polypeptide being 10 to 150 amino acids in length; and

iii) a reconstituted in vitro translation system comprising recombinant proteins, at least one protease inhibitor and isotopically-depleted amino acids;

b) introducing said first and second nucleic acid sequences into said reconstituted translation system under conditions such that said wild-type and truncated polypeptides are produced, said wild-type and truncated polypeptides comprising isotopically-depleted amino acids; and

c) determining the molecular mass of said truncated polypeptide by mass spectrometry.

6. A method, comprising:

a) providing:

i) a nucleic acid sequence encoding a polypeptide, said polypeptide being between 10 and 150 amino acids in length; and

ii) a reconstituted in vitro translation system lacking natural amino acids and comprising recombinant proteins, at least one protease inhibitor and isotopically-depleted amino acids;

b) introducing said nucleic acid into said reconstituted translation system under conditions such that said polypeptide is produced, said polypeptide comprising isotopically-depleted amino acids; and

c) determining the molecular mass of said polypeptide by mass spectrometry.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 13, 2012
From: AMBERGEN INCORPORATED
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028775/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2006
From: GARVIN, ALEX M.; GITE, SADANAND; BERGO, VLADISLAV B.; ROTHSCHILD, KENNETH J.
To: AMBERGEN, INC.
Reel/Frame 018641/0617 →
Continuity (3)
Continuation In Part PCTUS200502689500 · Jul 28, 2005
Continuation 1090361200 · Jul 30, 2004
Related Publication 20070072214A1 · Mar 29, 2007